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Background: This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in
patients with HER2-positive advanced breast cancer (ABC).
Methods: Eligible patients received sunitinib 37.5 mg/day and trastuzumab administered either weekly (loading,
4 mg/kg; then weekly 2 mg/kg) or 3-weekly (loading, 8 mg/kg; then 3-weekly 6 mg/kg). Prior trastuzumab and/or
lapatinib treatment were permitted. The primary endpoint was objective response rate (ORR).
Results: Sixty patients were enrolled and evaluable for safety; 57 were evaluable for efficacy. The majority of
patients (58%) had received no prior chemotherapy in the metastatic setting. The ORR was 37%; the clinical benefit
rate (CBR; percent objective response plus stable disease ≥ 24 weeks) was 56%. Among patients who were
treatment-naïve or had received only adjuvant therapy, the ORR was 44% and the CBR was 59%. Overall, median
overall survival had not been reached and the 1-year survival rate was 91%. The majority of adverse events (AEs)
were mild to moderate in severity. Forty percent of patients experienced AEs related to measured left ventricular
ejection fraction (LVEF) declines, which occurred more frequently in patients who had received prior anthracycline
treatment. Ten percent of patients exhibited symptoms related to LVEF declines. One patient died on study from
cardiogenic shock. Antitumor response and several safety parameters appeared to correlate with sunitinib exposure.
Conclusions: Sunitinib plus trastuzumab demonstrated antitumor activity in patients with HER2-positive ABC,
particularly those who were treatment-naïve or had only received prior adjuvant treatment. Sunitinib plus
trastuzumab had acceptable safety and tolerability in patients with HER2-positive ABC who had not received prior
anthracycline therapy.
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Trastuzumab is approved in combination with taxanes
for first-line treatment and as monotherapy for second-
line treatment of HER2-positive metastatic breast cancer
(MBC). Objective response rates (ORRs) for patients with
MBC receiving trastuzumab monotherapy were 26% in
the first-line setting [1] and approximately 15% in the
second-line setting [2,3]. However, resistance to trastuzu-
mab alone or in combination with chemotherapy generally
develops within 1 year of initiating treatment [1,2,4-6].
Sunitinib malate (SUTENT®; Pfizer Inc., New York,
NY, USA), an oral, multitargeted tyrosine kinase inhibi-
tor (TKI) of vascular endothelial growth factor recep-
tors (VEGFRs), platelet-derived growth factor receptors
(PDGFRs), and other receptor tyrosine kinases [7-12], is
approved multinationally for the treatment of advanced
renal cell carcinoma (RCC), imatinib-resistant/-intolerant
gastrointestinal stromal tumor (GIST), and progressing
metastatic pancreatic neuroendocrine tumor. In a phase II
study of heavily pretreated patients with MBC (N = 64),
single-agent sunitinib at 50 mg/day on Schedule 4/2
(4 weeks on treatment followed by 2 weeks off treatment)
demonstrated antitumor activity (ORR, 11%; clinical bene-
fit rate [CBR; percent objective responses plus stable
disease (SD) ≥ 24 weeks], 16%) [13]. In some patients in
this trial, tumor regrowth was observed during the
period off treatment following initial shrinkage on treat-
ment. Sunitinib administration at 37.5 mg on a continu-
ous daily dosing (CDD) schedule has also been found to
be active and feasible in RCC, GIST, and pancreatic neu-
roendocrine tumor [14-17], and was used subsequently in
sunitinib trials in MBC.
Preclinical and clinical data support the rationale that
concurrent inhibition of VEGF and HER2 signaling may
be more efficacious than inhibition of either target alone
[18-21]. VEGF may in part mediate the aggressive breast
cancer (BC) phenotype associated with HER2 overexpres-
sion [18,19], and constitutively active HER2 has been
shown to increase VEGF protein synthesis levels in human
BC cells [20].
In a mouse model of HER2-amplified BC, sunitinib
plus trastuzumab elicited a 75–80% greater decrease in
tumor volume than either agent alone (Pfizer Inc., data
on file). A phase II study of the anti-VEGF monoclonal
antibody bevacizumab and trastuzumab as first-line ther-
apy for HER2-positive MBC yielded an ORR of 46% [21],
which compared favorably with results obtained with tras-
tuzumab alone in other studies [1,22]. Preliminary results
of a phase III study also suggested that addition of bevaci-
zumab to the combination of trastuzumab and docetaxel
in a similar setting leads to modest improvements in clin-
ical outcomes [23]. Since preclinical studies had demon-
strated that dual inhibition of the VEGF and PDGF
signaling pathways provide greater antitumor activity thaninhibition of either pathway alone [24,25], it was hypothe-
sized that the addition of the multitargeted TKI sunitinib
to a trastuzumab-based regimen would be especially
efficacious.
The current phase II study evaluated the efficacy and
safety/tolerability of sunitinib on a CDD schedule in com-
bination with trastuzumab, weekly or every 3 weeks, in pa-
tients with HER2-positive advanced (metastatic or locally
recurrent) BC (ABC). The primary objective of the study
was to determine the antitumor activity of the combin-
ation. Sunitinib is not approved for ABC, and Pfizer did
not submit a request for regulatory review of sunitinib in
ABC by the FDA or other regulatory bodies. This decision
was made following the findings that sunitinib did not




Key inclusion criteria: Eligible patients were female aged ≥
18 years with histologically or cytologically proven, unre-
sectable, locally recurrent or metastatic HER2-positive BC
and measurable disease based on Response Evaluation
Criteria in Solid Tumors (RECIST) [30]. The study also
included patients who may have had prior trastuzumab
and/or lapatinib treatment in the neoadjuvant, adjuvant,
or metastatic disease setting, or prior treatment with
hormone therapy in the adjuvant and/or advanced dis-
ease setting. Patients were required to have an Eastern
Cooperative Oncology Group performance status of 0
or 1 with adequate organ function (including left ven-
tricular ejection fraction [LVEF] ≥ 55%) and resolution
of all acute toxic effects of prior therapy or surgical proce-
dures to National Cancer Institute Common Terminology
Criteria for Adverse Events, version 3.0 (NCI CTCAE
v3.0) grade ≤ 1 (except alopecia).
Key exclusion criteria: Patients with prior treatment
with more than one regimen of cytotoxic therapy for
advanced disease or prior treatment with sunitinib (or
trastuzumab if there was a history of hypersensitivity re-
actions) were excluded, as were patients with prior sys-
temic therapy, radiation therapy, or surgery ≤ 3 weeks
before the first dose of study treatment (prior palliative
radiotherapy to non-target metastatic lesions was per-
mitted). Brain metastases and cardiovascular disease or
uncontrolled hypertension were also exclusion criteria.
This study was conducted in accordance with the
International Conference on Harmonisation Good Clinical
Practice guidelines, the Declaration of Helsinki, and ap-
plicable local regulatory requirements and laws. Approval
from the institutional review board (IRB) or independent
ethics committee (IEC) of each participating center was
required. All patients gave written, informed consent prior
to enrollment.
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Originally developed using a randomized, placebo-
controlled design (control arm: trastuzumab plus pla-
cebo; test arm: trastuzumab plus sunitinib), the study
was subsequently changed to an open-label, single-arm
design in response to evolving standards of care in which
single-agent trastuzumab was considered suboptimal for
patient treatment. As such, with the control arm consist-
ing of trastuzumab as the only active agent, patient re-
cruitment was limited. Under these circumstances, the
control arm was removed, while the test arm (trastuzumab
plus sunitinib) was retained in the revised single-arm
study. The primary endpoint was ORR based on RECIST.
Secondary endpoints included duration of tumor response,
CBR, progression-free survival (PFS), overall survival (OS),
safety, pharmacokinetics (PK), and patient-reported out-
comes (PROs). The final protocol was approved by the
IRB and/or IEC at each participating center.Study-drug administration
Sunitinib 37.5 mg was taken orally once daily in the
morning, without regard to meals; a cycle was consid-
ered to be 4 weeks. Patients were monitored for toxicity;
1-week dosing interruptions were permitted for dose-
limiting toxicities. Dose reduction to 25 mg/day was
permitted for recurring grade 3/4 toxicity. Dose escal-
ation to 50 mg/day was permitted after two treatment
cycles with minimal treatment-related side effects. Fur-
ther dose titration was permitted in subsequent cycles
based on tolerability.
Trastuzumab was administered intravenously starting on
cycle 1, day 1 (C1D1), on either a weekly schedule (loading
dose, 4 mg/kg on day 1; maintenance dose, 2 mg/kg on
days 1, 8, 15, and 22 every 4 weeks) or a 3-weekly schedule
(loading dose, 8 mg/kg on day 1; maintenance dose, 6 mg/
kg every 3 weeks), as a previous study had shown no differ-
ence in efficacy or safety between the two schedules [22].
No dose modification was permitted, but dosing could be
delayed depending on tolerability.Study assessments
Tumor assessments were performed using computed
tomography or magnetic resonance imaging at baseline
and every 8 weeks, and evaluated by the investigator using
RECIST. Objective responses were confirmed ≥ 4 weeks
after initial documentation.
Safety was evaluated at regular intervals by monitoring
adverse events (AEs; NCI CTCAE v3.0), hematology,
and blood chemistry, and by physical examinations. QTc
intervals were monitored using triplicate 12-lead elec-
trocardiograms. LVEF was assessed using multigated ac-
quisition or echocardiogram scanning at screening, on
day 1 of odd-numbered treatment cycles beginning withC3, as clinically indicated, and when treatment was
discontinued.
Blood samples were collected pre-dose on C3D1 and
C5D1 to evaluate trough concentrations of sunitinib and
the active metabolite SU12662 using a validated, sensitive,
and specific liquid chromatography-tandem mass spectro-
metric method (Bioanalytical Systems Inc; Lafayette, IN,
USA) with acceptable accuracy and precision of quality
control samples for sunitinib (0.7–1.7% and ≤ 6.6%, re-
spectively) and SU12662 (−1.5% to 1.3% and ≤ 8.0%).
PROs were assessed using the self-administered European
Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire C30 (EORTC QLQ-C30)
and the related BC module BR23. EORTC QLQ-C30 as-
sesses global health status, five functional domains (phys-
ical, role, cognitive, emotional, and social), eight symptom
domains (fatigue, pain, nausea, appetite loss, constipation,
diarrhea, dyspnea, and insomnia), and financial difficulties.
BR23 assesses disease-related symptoms. Significant change
was defined as both a clinically meaningful change of ≥ 10
points (minimum important difference) [31] and a 95%
confidence interval (CI) for change from baseline not con-
taining zero. Questionnaires were completed by patients
on day 1 of each odd-numbered treatment cycle and at
the end of treatment or withdrawal from the study.
Statistical analysis
The historical trastuzumab ORR was assumed to be ≤ 20%
[1-3] and the predicted ORR for sunitinib plus trastuzu-
mab to be ≥ 33%. A sample size of ≥ 53 was required to
have 80% power at a 10% significance level to detect a 13%
improvement in ORR. The lower bound of the 95% CI of
the ORR was required to be > 13% to reject the null hy-
pothesis that the ORR of sunitinib plus trastuzumab
was no different than that of the historical single-agent
trastuzumab ORR.
The intention-to-treat population was the primary
population for the evaluation of efficacy endpoints and
patient characteristics. Exact two-sided 95% CIs for the
ORR and CBR were calculated using a method based on
the F distribution. Time-to-event endpoints were sum-
marized using the Kaplan–Meier method. One-year sur-
vival probability was estimated using the Kaplan–Meier
method, with a two-sided 95% CI calculated for the log
using a normal approximation and then back-transformed
to give a CI for the 1-year survival probability itself.
Steady-state dose-corrected trough plasma sunitinib
concentrations were derived using data from patients
who had taken sunitinib for ≥ 10 consecutive days by cor-
recting observed concentrations in patients who under-
went dosing modifications based on the 37.5-mg starting
dose (starting dose ÷ actual dose).
PRO data analysis was limited to the first seven cycles,
in which there were ≥ 10 patients.
Bachelot et al. BMC Cancer 2014, 14:166 Page 4 of 10
http://www.biomedcentral.com/1471-2407/14/166Results
Patient characteristics
Sixty patients with median age of 54 years (range 31–81)
and ECOG PS score of 0/1 in 52/58%, respectively, were
enrolled in the study at 17 centers across five countries
between May 2006 and July 2008: six on the original
protocol and 54 under the amended open-label design.
Patient demographics and baseline characteristics are
shown in Table 1. There were 33 subjects (55%) who
were estrogen receptor-positive and 22 subjects (37%)
who were progesterone receptor positive. All subjectsTable 1 Patient characteristics at baseline
Characteristic n (%)
Patients receiving treatment 60 (100)









Ductal and lobular 1 (2)




Estrogen receptor-positive 33 (55)
Progesterone receptor-positive 22 (37)
HER2-positive* 60 (100)
Prior systemic therapy 44 (73)
Anthracycline + trastuzumab or lapatinib 26 (43)
Anthracycline only 11 (18)
Trastuzumab only 4 (7)
Lapatinib only 2 (3)
Other 1 (2)
No prior systemic therapy 16 (27)








Abbreviation: ECOG PS Eastern Cooperative Oncology Group performance status.
*IHC 3+: 52 (87%); IHC 2+ 6 (10%); FISH+: 22 (37%).were HER2 positive by either FISH or IHC. The majority
of patients (58%) had received no prior chemotherapy in
the metastatic setting.
Treatment received
Fifty-seven patients received the sunitinib–trastuzumab
combination, making them evaluable for efficacy. Three
patients received only trastuzumab. All 60 patients were
evaluable for safety/tolerability. By data cut-off (October
2010), two patients had completed the study after receiving
18 months of study treatment and the remaining 58
patients had discontinued treatment: 44 due to disease
progression, 11 due to AEs, and one each to death,
consent withdrawal, and other (unspecified) reasons.
Median treatment duration was 3.9 months (range:
0.5–15.7). Among the 57 patients who received the
sunitinib–trastuzumab combination, most (63%) had
at least one sunitinib dosing interruption, with a median
length of interruption of 8 days (range: 4–46). The suniti-
nib dose was reduced to 25 mg in 22 patients (39%) and
subsequently to 12.5 mg in three patients (5%). Among
the 60 patients who received trastuzumab, dosing was de-
layed by ≥ 1 week in 18 patients (30%). The median rela-
tive dose intensity was 72% (range: 47–127%) for sunitinib
and 96% (range: 60–122%) for trastuzumab.
Efficacy
The confirmed ORR in the efficacy-evaluable population
was 37%, with a CBR of 56% (Table 2). The median dur-
ation of response was 5.9 months (95% CI: 5.2–7.6). The
majority of confirmed responses (71%; 15/21 patients)
were reported among patients who were treatment-naïve
or had received only adjuvant therapy. For this group,
the ORR was 44% and the CBR was 59%. The ORR was
numerically higher among patients with visceral versus
non-visceral disease (44% vs. 19%, respectively) and among
those with estrogen-receptor-negative versus -positive dis-
ease (41% vs. 33%). Overall, the majority of patients (43/57
evaluable patients, 75%) had reductions in tumor size over
the course of the study (Figure 1A).
At a median duration of follow-up of 24.4 months (95%
CI: 24.2–24.9), median PFS was 6.4 months (Figure 1B).
Median OS had not yet been reached (Figure 1C); the
1-year survival rate was 91% (95% CI: 80–96%).
Safety
The most commonly reported non-hematologic AEs of
any cause were fatigue/asthenia (75%), diarrhea (60%), and
stomatitis/related oral disorders (53%; Table 3). The most
common non-hematologic grade 3 AEs were fatigue/
asthenia (20%), hypertension (13%), and decreased ap-
petite (7%). There were six non-hematologic grade 4
AEs (LVEF decline, pulmonary embolism, hyponatre-
mia, multi-organ failure, aspartate aminotransferase


















(n = 57) (n = 34) (n = 23) (n = 41) (n = 16) (n = 30) (n = 27)
Complete response 2 (4) 2 (6) 0 1 (2) 1 (6) 2 (7) 0
Partial response 19 (33) 13 (38) 6 (26) 17 (41) 2 (13) 8 (27) 11 (41)
Stable disease 21 (37) 10 (29) 11 (48) 15 (37) 6 (38) 13 (43) 8 (30)
24 weeks 11 (19) 5 (15) 6 (26) 6 (15) 5 (31) 6 (20) 5 (19)
Objective response 21 (37) 15 (44) 6 (26) 18 (44) 3 (19) 10 (33) 11 (41)
95% exact CI 24–51 27–62 10–48 28–60 4–46 17–53 22–61
Clinical benefit‡ 32 (56) 20 (59) 12 (52) 24 (59) 8 (50) 16 (53) 16 (59)
95% exact CI 42–69 41–75 31–73 42–74 25–75 34–72 39–78
*Chemotherapy, trastuzumab, and/or lapatinib.
†Liver and/or lung.
‡Objective response or stable disease ≥ 24 weeks.
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from cardiogenic shock; prior to enrolling in the present
study, this patient had received a combination of fluoro-
uracil, cyclophosphamide, and epirubicin in the adjuvant
setting and trastuzumab followed by lapatinib in the
advanced/metastatic setting.
Eleven patients discontinued the study and 18 patients
permanently discontinued treatment with one or both
study drugs due to AEs considered treatment-related. AEs
resulted in temporary treatment discontinuations and/or
dose reductions of one or both study drugs in 48 patients.
AEs related to measured LVEF declines were reported
in 24 patients (40%) during the study (Table 4). How-
ever, these were asymptomatic (CTCAE grade 1/2) in 18
patients (30%); only 10% of patients exhibited symptoms
related to LVEF declines. LVEF decline occurred more
frequently in patients who had received prior treatment
with anthracyclines alone or combined with trastuzumab
(55% and 50%, respectively) compared with patients who
had received neither type of agent or trastuzumab only
(26% and 0%). Median LVEF for the whole group was
63% at baseline; during C3, C5, C7, and C9, and at the
end of treatment, it was at or above the lower limit of
normal (range: 55–60%).
Pharmacokinetics
Mean dose-corrected, steady-state trough plasma con-
centrations (coefficient of variation) of sunitinib, the ac-
tive metabolite SU12662, and total drug (sunitinib plus
SU12662) were 53.5 (52%), 26.7 (54%), and 80.2 (50%)
ng/mL on C3D1 (n = 18); and 55.0 (45%), 24.7 (51%),
and 79.7 (46%) ng/mL on C5D1 (n = 13), respectively.
Effect of total-drug exposure on efficacy and safety
Among patients with trough plasma drug concentration
measurements on C3D1 or C5D1, the ORR was higherin patients with total-drug trough concentrations above
the median (higher-exposure sub-group) than below the
median (lower-exposure sub-group; Table 5). SD rates
were lower in the former than the latter PK sub-group.
CBRs (defined in these analyses as percentages of patients
with objective responses or SD ≥ 12 weeks) were similar in
the two PK sub-groups. Median PFS was longer in the
sub-group with higher exposure on C5D1 (p = 0.013;
Table 5).
The effect of total-drug trough concentrations on
C3D1 (n = 29) and C5D1 (n = 18) on the incidences of
specific AEs reported in C1–C4 was also evaluated. In-
cidences of asthenia (any grade) and leukopenia (any
grade and grade 3/4) appeared to be similar or higher in
the higher-exposure sub-group. Incidences of any grade
and grade 3/4 hypertension and thrombocytopenia ap-
peared to be consistently higher in the higher-exposure
sub-group. No lymphopenia was reported in either sub-
group, and no consistent trends were observed with re-
spect to the incidences of decreased ejection fraction or
neutropenia reported as AEs. Correlative analyses showed
moderate to strong correlations between total-drug trough
concentrations and a number of key safety parameters
(reduced neutrophil and leukocyte counts, elevated sys-
tolic or diastolic blood pressure, and reduced LVEF), par-
ticularly on C5D1 (Table 6).
Patient-reported outcomes
Mean changes from baseline in EORTC QLQ-C30
functional and symptom scores and in BR23 scores
were analyzed. Overall, PROs appeared to be mixed in
the study, with some functional domains and symptoms
improving during treatment and others (particularly diar-
rhea) worsening.
Among EORTC QLQ-C30 functional scores, emotional
function showed clinically meaningful improvement on
Figure 1 Antitumor activity of sunitinib plus trastuzumab. (A) Maximum reduction in target lesion size by patient, with confirmed responses
based on RECIST indicated. Broken gray lines indicate cut-offs for progressive disease and partial responses. (B) and (C) Kaplan–Meier estimates of
(B) progression-free survival and (C) overall survival. RECIST, Response Evaluation Criteria in Solid Tumors.
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Table 3 Non-hematologic adverse events (AEs) and




Grade 1/2 Grade 3 Grade 4 Any
grade
Non-hematologic AEs of any cause occurring in ≥ 15% of patients
Fatigue/asthenia 33 (55) 12 (20) 0 45 (75)
Diarrhea 33 (55) 3 (5) 0 36 (60)
Stomatitis, oral discomfort,
and related oral syndromes
29 (48) 3 (5) 0 32 (53)
Dysgeusia 27 (45) 0 0 27 (45)
Hypertension 18 (30) 8 (13) 0 26 (43)
Skin and subcutaneous
tissue disorders
25 (42) 0 0 25 (42)
Vomiting 19 (32) 2 (3) 0 21 (35)
Dyspepsia 20 (33) 0 0 20 (33)
Epistaxis 18 (30) 2 (3) 0 20 (33)
Nausea 20 (33) 0 0 20 (33)
Headache 17 (28) 2 (3) 0 19 (32)
Decreased appetite 14 (23) 4 (7) 0 18 (30)
Dry skin 14 (23) 1 (2) 0 15 (25)
Ejection fraction decreased 10 (17) 3 (5) 1 (2) 14 (23)
Abdominal pain 11 (18) 0 0 11 (18)
Hand–foot syndrome and
related disorders
8 (13) 3 (5) 0 11 (18)
Pyrexia 11 (18) 0 0 11 (18)
Weight decreased 11 (18) 0 0 11 (18)
Constipation 10 (17) 0 0 10 (17)
Left ventricular dysfunction 8 (13) 2 (3) 0 10 (17)
Insomnia 8 (13) 1 (2) 0 9 (15)
Dyspnea 8 (13) 1 (2) 0 9 (15)
Hematologic laboratory abnormalities
Leukopenia 46 (77) 4 (7) 1 (2) 51 (85)
Anemia 46 (77) 2 (3) 0 48 (80)
Neutropenia 36 (60) 9 (15) 1 (2) 46 (77)
Lymphopenia 36 (60) 6 (10) 1 (2) 43 (72)
Thrombocytopenia 34 (57) 6 (10) 3 (5) 43 (72)
Table 4 LVEF decline* by prior treatment
n (%)
Prior treatment† n Asymptomatic‡ Symptomatic‡ Total
None 19 5 (26) 0 5 (26)
Trastzumab only 4 0 0 0
Anthracycline only 11 5 (45) 1 (9) 6 (55)
Trastuzumab and
anthracycline
26 8 (31) 5 (19)§ 13 (50)
All patients 60 18 (30) 6 (10)¶ 24 (40)
Abbreviations: AE adverse event, CTCAE Common Terminology Criteria for
Adverse Events, LVEF left ventricular ejection fraction.
*Reported as an AE.
†Trastuzumab and/or anthracycline.
‡Asymptomatic, CTCAE grade 1/2; symptomatic, CTCAE grade 3/4.
§One fatal event occurred (cardiogenic shock).
¶Three of six of these patients discontinued the study due to LVEF decline.
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exhibited clinical meaningful worsening on C3D1 and
C5D1. Among symptom scores, pain (C3D1 and C5D1)
and insomnia (C5D1 and C7D1) showed improvement.
Worsening was observed in fatigue (C3D1) and diarrhea
(C3D1, C5D1, and C7D1). Among BR23 scores, improve-
ment was observed in breast symptoms (C3D1, C5D1,
and C7D1) and arm symptoms (C5D1). Sexual enjoyment
(among those who reported being sexually active) and sys-
temic therapy side effects worsened by C3D1. No other
clinically meaningful changes in EORTC QLQ-C30 or
BR23 scores were observed.Discussion
Sunitinib 37.5 mg on a CDD schedule in combination
with trastuzumab (weekly or 3-weekly) demonstrated
substantial antitumor activity in patients with ABC, with
an ORR of 37% and a CBR of 56%. The null hypothesis
that the ORR of the sunitinib − trastuzumab combination
was no different than the historical trastuzumab ORR was
therefore rejected. A 1-year survival rate of 91% was
achieved, and median OS was not reached (survival
was only followed for 2 years post-dose).
The ORR of the combination was greater than the
11% ORR reported in two previous studies of sunitinib
monotherapy (administered at 50 mg/day on Schedule 4/2
or 37.5 mg/day on a CDD schedule) in previously treated
patients with ABC [13,32]. In the current study, most re-
sponses (71%) were noted in treatment-naïve patients and
in patients who had received only prior adjuvant therapy.
These patients achieved an ORR of 44%, similar to that
observed in an earlier trial of first-line bevacizumab plus
trastuzumab (46%) [21]. The high ORR obtained with the
sunitinib–trastuzumab combination in patients with vis-
ceral disease (44%) was also encouraging. These observa-
tions provide additional support for synergy between
tumor-specific HER2-targeted and antiangiogenic therap-
ies for aggressive disease, as predicted in preclinical stud-
ies (Pfizer Inc., data on file). In particular, the action of
sunitinib on both vascular endothelial cells and pericytes
[7,8,33] as a result of dual targeting of VEGFR and PDGFR
may complement HER2-targeting by trastuzumab, al-
though trastuzumab resistance did not appear to be over-
come in patients receiving the combination as second-line
therapy.
In general, the sunitinib − trastuzumab combination
appeared to have an acceptable safety profile that was
broadly consistent with the profiles of both drugs ad-
ministered as monotherapy [13,32,34], with the majority
of AEs being of mild to moderate severity. Dosing modi-
fications were frequently used to manage AEs, with 80%
Table 5 Effect of total-drug* exposure on antitumor activity
C3D1 C5D1
Efficacy parameter† No. of evaluable patients No. with parameter (%) No. of evaluable patients No. with parameter (%)
Objective response
< Median trough concentation 14 4 (29) 9 3 (33)
≥ Median trough concentation 15 10 (67) 9 7 (78)
Stable disease
< Median trough concentation 14 8 (57) 9 6 (67)
≥ Median trough concentation 15 3 (20) 9 2 (22)
Clinical benefit‡
< Median trough concentation 14 11 (79) 9 9 (100)
≥ Median trough concentation 15 13 (87) 9 9 (100)
Median PFS (95% CI), months
< Median trough concentation 14 6.6 (4.9–9.5) 9 7.2 (6.0–7.3)
≥ Median trough concentation 15 7.3 (6.4–10.2)§ 9 9.5 (8.1–10.7)¶
Abbreviations: C cycle, D day, PFS progression-free survival.
*Sunitinib + SU12662.
†By trough concentration of total drug on C3D1 or C5D1 as indicated.
‡Patients with objective responses or stable disease ≥ 12 weeks.
§Log-rank p = 0.879.
¶Log-rank p = 0.013.
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tions and/or dose reductions of one or both study drugs
due to AEs.
Cardiac dysfunction is a known side effect of trastu-
zumab, with reported incidences of 3–7% when given
as monotherapy and 27% when administered with
anthracycline-containing chemotherapy [35]. Cardiac
dysfunction has also been associated with sunitinib
treatment, with reported incidences of 11–19% in pa-
tients with RCC or GIST [36-38]. Given that the drugs
were used in combination in this study, LVEF was
monitored frequently. Forty percent of patients (24/60)
experienced AEs related to measured LVEF declines,
although in the majority of these patients (75%) theTable 6 Correlation between trough concentration of
total drug* and change in laboratory parameters
Laboratory parameter† Pearson correlation coefficient (R)‡
C3D1 (n = 29) C5D1 (n = 18)
Absolute neutrophil count 0.15 −0.64
Leukocyte count 0.20 −0.79
Lymphocyte count 0.12 −0.21
Thrombocyte count −0.33 −0.40
Systolic blood pressure 0.18 0.68
Diastolic blood pressure 0.06 0.51
Ejection fraction −0.61 −0.21
Abbreviations: C cycle, D day.
*Sunitinib + SU12662.
†Based on percent change from baseline.
‡Weak correlation, |R| <0.50; moderate correlation, 0.50 ≤ |R| < 0.75; strong
correlation, |R| ≥ 0.75.events were asymptomatic (CTCAE grade 1/2), with
measured changes in LVEF during the events being be-
tween −4% and −37% relative to baseline. Pre-exposure
to anthracyclines appeared to be a major factor con-
tributing to cardiac dysfunction: 19 of the 24 patients
with LVEF-related AEs overall (79%) and all six with
symptomatic LVEF-related events had received prior
anthracycline treatment, either with or without prior
trastuzumab therapy. Of the 23 patients in the study
who had not received prior anthracyclines, only five
experienced LVEF-related AEs (22%). This rate of
LVEF decline following prior anthracycline treatment
was consistent with that reported in other studies
using trastuzumab [2,22]. Median baseline LVEF was
similar between the 37 patients who had received prior
anthracyclines and the 23 who had not (61% vs. 64%).
In total, five patients (8%) discontinued the present
study for reasons related to cardiac dysfunction: three
discontinued due to measured LVEF declines (ranging
from −18% to −30% relative to baseline), one due to
acute heart failure (with an LVEF decline of 27%), and
one due to asthenia, cardiac insufficiency, and dyspnea
(with an LVEF decline of 37%). Additionally, as noted
above, one patient died due to cardiogenic shock (with a
change in LVEF from 54% at screening to 23% 3 days
prior to death). In the majority of the 24 patients with
LVEF-related AEs (67%), the events resolved either
spontaneously or following temporary or permanent
discontinuation of trastuzumab (and, in one case, suni-
tinib as well), in contrast to cardiac dysfunction associated
with anthracycline treatment, which is usually irreversible
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cluding the high rate of grade 3/4 cardiotoxicity in
anthracycline-exposed patients, indicate that great
caution along with proactive cardiac monitoring and
management of cardiotoxicity by treatment interruption/
discontinuation are critical when using a drug combin-
ation such as that tested in this study.
Steady-state concentrations of sunitinib, the active
metabolite SU12662, and total drug were consistent with
those obtained with single-agent sunitinib administered at
50 mg/day on Schedule 4/2 to patients with MBC [13].
Pharmacokinetic evaluations suggested that no clinically
relevant drug − drug interactions had occurred. In addition,
antitumor response appeared to correlate with plasma drug
exposure: ORR and PFS appeared to be greater in patients
with higher plasma drug exposures. Correlations were also
observed between plasma drug exposures and several key
safety parameters.
In conclusion, sunitinib on a CDD schedule in combin-
ation with trastuzumab (weekly or 3-weekly) demon-
strated antitumor activity in patients with HER2-positive
ABC, particularly in those who were treatment-naïve or
had only received prior adjuvant treatment. Sunitinib plus
trastuzumab had acceptable safety and tolerability in pa-
tients with ABC who had not received prior anthracycline
therapy. The regimen is not being developed further, how-
ever, based on disappointing results obtained in four phase
III studies of sunitinib in patients with ABC [26-29].
Nevertheless, the results obtained in this study contribute
to the field of antiangiogenesis by adding to the evidence
supporting a beneficial effect of targeting both the VEGF
and HER2 pathways and by providing a platform for
further exploration with other agents that may lead to
benefit in specific patient populations.
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